Cancer/testis antigens for therapeutic use.
Since van der Bruggen and colleagues first identified specific human tumour-associated antigens of the MAGE family, numerous potential immunotherapeutic targets have been discovered, often belonging to the so-called cancer/ testis gene family. Several members of this group have been described as immunogenic and have been utilised in clinical trials. In a search for interesting targets within this family, our laboratory has focussed its works for a number of years on two novel cancer/testis antigens called T21 and HAGE. In this article, we will focus our discussion on their levels of expression in a wide variety of both normal and cancer tissues, their possible role in tumour cell development and proliferation, and their immunogenic potential.
Mathieu
M G
MG
The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK. morgan.mathieu2@ntu.ac.uk
Miles
A K
AK
Li
G
G
McArdle
S E B
SE
Rees
R C
RC
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D002874:Chromosome Mapping; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D008297:Male; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D013737:Testis / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology
D000951:Antigens, Neoplasm